APA (7th ed.) Citation

DO, P., CD, J., SR, C., R, U., CMJ, W., NR, W., . . . SW, W. (2025). Body fluid biomarkers and psychosis risk in The Accelerating Medicines Partnership® Schizophrenia Program: Design considerations. Schizophrenia (Heidelberg, Germany), 11(1), 78. https://doi.org/10.1038/s41537-025-00610-4

Chicago Style (17th ed.) Citation

DO, Perkins, et al. "Body Fluid Biomarkers and Psychosis Risk in The Accelerating Medicines Partnership® Schizophrenia Program: Design Considerations." Schizophrenia (Heidelberg, Germany) 11, no. 1 (2025): 78. https://doi.org/10.1038/s41537-025-00610-4.

MLA (9th ed.) Citation

DO, Perkins, et al. "Body Fluid Biomarkers and Psychosis Risk in The Accelerating Medicines Partnership® Schizophrenia Program: Design Considerations." Schizophrenia (Heidelberg, Germany), vol. 11, no. 1, 2025, p. 78, https://doi.org/10.1038/s41537-025-00610-4.